HR 3674
Global Alzheimer’s Initiative Now Act
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill authorizes the United States to participate in the Davos Alzheimer’s Collaborative (DAC), a global initiative focused on preventing, diagnosing, and treating Alzheimer’s disease and dementia. It aims to increase U.S. contributions to DAC, which is working to develop diagnostics and treatments for diverse populations worldwide. The bill also directs the President to designate a representative to serve on the DAC’s advisory and governing boards and requires regular reporting to Congress on U.S. involvement and funding.
Key provisions
- Authorizes U.S. participation in the Davos Alzheimer’s Collaborative (DAC).
- Directs the President to designate a U.S. representative to serve on the DAC’s advisory and governing boards.
- Authorizes appropriations for U.S. contributions to DAC.
- Establishes a limit on U.S. contributions to DAC, ensuring they don’t exceed 33% of total funding by 2030.
- Requires the President to submit annual reports to Congress detailing U.S. involvement and funding.
- Defines ‘appropriate congressional committees’ for reporting purposes.
- Encourages coordination between DAC and existing U.S. global health and Alzheimer’s research programs.
- Promotes international development cooperation related to Alzheimer’s research and treatment.
Who is affected
- Individuals with Alzheimer’s disease and dementia
- Families and caregivers of individuals with Alzheimer’s disease and dementia
- Healthcare systems globally
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Eleanor Holmes [D-DC-At Large] Norton
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
119th CONGRESS — 1st Session
H. R. 3674
IN THE HOUSE OF REPRESENTATIVES
A BILL
To authorize United States participation in the Davos Alzheimer’s Collaborative.
This Act may be cited as the Global Alzheimer’s Initiative Now Act
.
Congress finds the following:
Alzheimer’s disease and dementia currently afflicts nearly 60 million people across the globe, a number that is projected to jump to more than 150 million by 2050.
There are now more global cases of Alzheimer’s disease and dementia than cancer and HIV combined, with 39 million diagnosed cases of HIV/AIDS and 20 million cases of cancer in 2022.
The pace of populations aging will challenge countries’ sovereign funds and health and social safety systems.
By 2050, the world’s population of people aged 60 years and older will double to 1.6 billion and reach a proportion of 22 percent of the world’s population. While the number of persons aged 80 or older is expected to triple by 2050.
Every year, Alzheimer’s disease and dementia costs the global economy more than $1.3 trillion and this is doubling every decade.
Women are disproportionately affected by Alzheimer’s disease and dementia, both directly and indirectly. Women experience higher disability-adjusted life years and mortality due to Alzheimer’s disease and dementia, but also provide 70 percent of care hours for people living with Alzheimer’s disease and dementia.
The Davos Alzheimer’s Collaborative (DAC) is a public-private-patient venture, launched in 2021, that is transforming Alzheimer’s disease and dementia research, prevention, and care in low-income, middle-income, and high-income settings globally.
DAC seeks to raise and deploy over $700 million over 6 years to accelerate innovation in drug development and transform the way healthcare systems prevent, diagnose, and treat Alzheimer’s disease and dementia for all people in all places.
In 2023, DAC supported 19 healthcare systems in 12 countries, including the United States.
The United States Government has traditionally been the largest funder of global health programs, with approximately $12 billion in funding in fiscal year 2024 for programs that cover the full range of global health challenges.
It shall be the policy of the United States—
to lead global cooperative efforts to combat Alzheimer’s disease and dementia, including in countries with low-income economies and countries with middle-income economies (as such terms are defined by the World Bank) that represent the majority of future cases; and
to lead multilateral health initiatives, including the Davos Alzheimer’s Collaborative—
to develop diagnostics and treatments for diverse populations in the United States and across the globe;
to promote international development cooperation; and
to provide substantial leverage and burden sharing for United States investments.
The President is authorized to designate an employee of the relevant Federal department or agency providing the majority of United States contributions to DAC to serve on the Advisory Council of DAC and, if nominated, on the Board of Directors of DAC, as a representative of the United States.
In carrying out this section, the individual designated pursuant to paragraph (1) shall coordinate with the USAID Administrator, the Secretary of State, and the Secretary of Health and Human Services to promote alignment, as appropriate, between DAC and United States global health and Alzheimer’s disease and dementia research and development programs.
Amounts authorized to be appropriated and made available to carry out chapters 1 and 10 of part I and chapter 4 of part II of the Foreign Assistance Act of 1961 (22 U.S.C. 2151 et seq.) are authorized to be made available for United States contributions to DAC.
Amounts made available under paragraph (1) may be obligated and expended only to the extent that DAC secures funding from sources other than the United States. At any time during fiscal years 2026 through 2030, no United States contribution to DAC may cause the total amount of United States Government contributions to DAC to exceed 33 percent of the total amount of funds contributed to the DAC from all sources.
Not later than 180 days after the date of the enactment of this Act, and on an annual basis thereafter, the President shall submit to the appropriate congressional committees a report that includes the following:
A description of any planned financial contributions from the United States Government to DAC.
The manner and extent to which the United States will participate in the governance of DAC.
A description of how participation in DAC supports relevant United States Government strategies and programs to combat Alzheimer’s disease and dementia and to promote global health.
In subsection (d), the term appropriate congressional committees means—
the Committee on Foreign Affairs and Committee on Appropriations of the House of Representatives; and
the Committee on Foreign Relations and the Committee on Appropriations of the Senate.